[ back to News ]

Concert Pharmaceuticals to Present at Epilepsy Pipeline Update Conference

January 30, 2012

Lexington, MA – Concert Pharmaceuticals, Inc. announced today that it will present at the 2012 Epilepsy Pipeline Update Conference.   Dr. Philip Graham, Concert’s Vice President of Program Development, will present at 11:30 am Pacific Time on Thursday, February 2, 2012 during the early drug pipeline session. The conference is being held February 2-4, 2012 in San Francisco, CA.

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert’s approach leverages decades of pharmaceutical and clinical experience to reduce the time, risk and expense needed to create important new medicines. The company has a broad research pipeline encompassing many therapeutic areas including antiviral disease, renal disease, and CNS disorders, among others. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.

Concert Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of Concert Pharmaceuticals, Inc.

[ back to top ]